

**IN THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. to 4. (Canceled)

5. (Currently amended) A method for evaluating a change in drug susceptibility of HIV, comprising:

- (i) collecting a sample from an HIV-infected patient;
- (ii) determining whether the sample comprises an HIV having a reverse transcriptase containing a mutation T386A as compared to the wild-type HIV strain IIIB/LAI;
- (iii) determining drug susceptibility of HIV to an HIV reverse transcriptase inhibitor in said sample;
- (iv) comparing drug susceptibility in said sample containing said mutation T386A with drug susceptibility in a sample containing a wild type HIV reverse transcriptase; and
- (v) correlating the presence of said mutation of step (ii) to a change in drug susceptibility of HIV to said inhibitor.

6. (Currently amended) A method of evaluating a change in drug susceptibility of HIV, comprising:

- (i) providing an HIV comprising a reverse transcriptase containing a mutation T386A as compared to the wild-type HIV strain IIIB/LAI;
- (ii) determining a phenotypic response of said HIV to an HIV reverse transcriptase inhibitor;
- (iii) determining drug susceptibility of said HIV to said inhibitor in said sample;
- (iv) comparing drug susceptibility in said sample containing said mutation T386A with drug susceptibility in a sample containing a wild type HIV reverse transcriptase; and
- (v) correlating the phenotypic response of step (ii) to a change in drug susceptibility of said HIV to said inhibitor.

7. to 10. (Canceled)